2008 was supposed to be Medipattern's (TSXV:MKI) big year. The Toronto based company, which designs medical imaging software, went public in 2005, … [Read more...] about 2012 an Important Year for Medipattern
Content brought to you by:
The Cantech Letter Life Sciences section is brought to you by Relay Medical Corp. (CSNX:RELA). Relay is in the business of commercializing innovative technologies, protected by issued and pending patents, in the medical diagnostics and research field with an emphasis on In Vitro Diagnostics (IVD) and Point of Care Testing (POCT). Click on the logo for more info...
Shares of CardioComm (TSXV:EKG) were on fire today after the company announced it had cleared an important hurdle in its goal to market a new handheld … [Read more...] about Investors Heart CardioComm, Device Maker Clears Important Hurdle
If you want telecom you go to Ottawa. If you want oil and gas technology, go to Alberta. When it comes to biotech, Quebec is Canada's undisputed … [Read more...] about Quebec’s Five Most Interesting Biotech Stocks
Neptune Technologies (TSXV:NTB) yesterday reported its Q3, 2012 results. The numbers appeared to be a mixed bag; revenue was up by 19% to $5.12 … [Read more...] about Byron Capital’s Douglas Loe says Neptune Technologies is a BUY
The long and winding road. Investors know progress in biotech can be painfully slow. Oncolytics Biotech (TSX:ONC) can trace its history all the way … [Read more...] about Oncolytics Biotech’s REOLYSIN Inches Closer to Reality
CAE Inc. (TSX:CAE), which was founded in 1947 in Saint-Hubert, Quebec has built a billion dollar business on the back of flight simulators. The … [Read more...] about Why is CAE betting so big on the Medical Simulation Market?
In a recent note to clients, Byron Capital's Healthcare and Biotech Analyst Douglas Loe reiterated his Speculative Buy target on Protox Therapeutics … [Read more...] about Byron Capital’s Douglas Loe: the Market is Undervaluing Protox Therapeutics
For Bioexx (TSX:BXI) shareholders, 2011 was a year to forget. Shuffling management, delays in bringing its Saskatchewan oilseed extraction plant up … [Read more...] about Is Bioexx a Takeover Candidate, or can it Rebound in 2012?
After a tough few years, the first half of 2011 showed signs of hope for shareholders of AEterna Zentaris (TSX:AEZ). In July, nearly eight years after … [Read more...] about Byron Capital: AEterna Zentaris is a Speculative Buy, Target Price $3.50
SXC Health's (TSX:SXC) meteoric rise, accomplished primarily through acquisition, has been nothing short of remarkable. The company, which was … [Read more...] about Versant Partners: There’s Still Upside in SXC Health